BioCentury
ARTICLE | Clinical News

Inovio's VGX-3100 meets in Phase II for cervical dysplasia

July 24, 2014 12:58 AM UTC

Inovio Pharmaceuticals Inc. (NYSE-M:INO) gained $1.96 (18%) to $13.10 on Wednesday after reporting that intramuscular VGX-3100 followed by electroporation with Inovio's Cellectra device met the primary endpoint vs. placebo in a Phase II trial to treat cervical intraepithelial neoplasia (CIN) associated with HPV types 16 or 18. VGX-3100 followed by electroporation at weeks 0, 4 and 12 led to a greater proportion of patients with histopathological regression of cervical dysplasia to CIN grade 1 or no disease at week 36 vs. placebo (49.5% vs. 30.6%, p<0.025). The double-blind, international trial enrolled 143 women with biopsy-proven CIN grade 2/3. Data were presented at the International Society of DNA Vaccines meeting in San Diego. ...